TY - JOUR
T1 - Association between coffee consumption and total dietary caffeine intake with cognitive functioning
T2 - cross-sectional assessment in an elderly Mediterranean population
AU - the PREDIMED-Plus Investigators
AU - Paz-Graniel, Indira
AU - Babio, Nancy
AU - Becerra-Tomás, Nerea
AU - Toledo, Estefania
AU - Camacho-Barcia, Lucia
AU - Corella, Dolores
AU - Castañer-Niño, Olga
AU - Romaguera, Dora
AU - Vioque, Jesús
AU - Alonso-Gómez, Ángel María
AU - Wärnberg, Julia
AU - Martínez, J. Alfredo
AU - Serra-Majem, Luís
AU - Estruch, Ramon
AU - Tinahones, Francisco J.
AU - Fernandez-Aranda, Fernando
AU - Lapetra, José
AU - Pintó, Xavier
AU - Tur, Josep A.
AU - García-Rios, Antonio
AU - Bueno-Cavanillas, Aurora
AU - Gaforio, José J.
AU - Matía-Martín, Pilar
AU - Daimiel, Lidia
AU - Sánchez, Vicente Martín
AU - Vidal, Josep
AU - Prieto-Sanchez, Lucía
AU - Ros, Emilio
AU - Razquin, Cristina
AU - Mestres, Cristina
AU - Sorli, José V.
AU - Cuenca-Royo, Aida M.
AU - Rios, Angel
AU - Torres-Collado, Laura
AU - Vaquero-Luna, Jessica
AU - Pérez-Farinós, Napoleon
AU - Zulet, M. Angeles
AU - Sanchez-Villegas, Almudena
AU - Casas, Rosa M.
AU - Bernal-Lopez, M. Rosa
AU - Santos-Lozano, José Manuel
AU - Corbella, Xavier
AU - Mateos, David
AU - Buil-Cosiales, Pilar
AU - Jiménez-Murcia, Susana
AU - Fernandez-Carrion, Rebeca
AU - Forcano-Gamazo, Laura
AU - López, Meritxell
AU - Zomeño, M. D.
AU - Hernaéz, A.
N1 - Funding Information:
JS-S serves on the board of (and receives grant support through his institution from) the International Nut and Dried Fruit Council and the Eroski Foundation. He also serves on the Executive Committee of the Instituto Danone, Spain, and on the Scientific Committee of the Danone International Institute. He has received research support from the Patrimonio Comunal Olivarero, Spain, and Borges S.A., Spain. He receives consulting fees or travel expenses from Danone, the Eroski Foundation, the Instituto Danone, Spain, and Abbot Laboratories. ER has received research funding through his institution from the California Walnut Commission, Folsom, CA, USA; was a paid member of its Health Research Advisory Group; and is a nonpaid member of its Scientific Advisory Council.
Funding Information:
The PREDIMED-Plus trial was supported by the Spanish government’s official funding agency for biomedical research, ISCIII, through the Fondo de Investigación para la Salud (FIS) and co-funded by European Union ERDF/ESF, “A way to make Europe”/ “Investing in your future” (five coordinated FIS projects led by JS-S and JVid, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560 and PI19/01332), the Special Action Project entitled: Implementación y evaluación de una intervención intensiva sobre la actividad física Cohorte PREDIMED-Plus grant to JS-S, the European Research Council (Advanced Research Grant 2013–2018, 340918) to MÁM-G, the Recercaixa Grant to JS-S (2013ACUP00194), grants from the Consejería de Salud de la Junta de Andalucía (PI0458/2013, PS0358/2016 and PI0137/2018), a grant from the Generalitat Valenciana (PROMETEO/2017/017), a SEMERGEN grant, and funds from the European Regional Development Fund (CB06/03). This research was also partially funded by EU-H2020 Grant (EAT2BENICE/H2020-SFS-2016–2; Ref 728018). Study resulting from the SLT006/17/00246 grant was funded by the Department of Health of the Generalitat de Catalunya by the call “Acció instrumental de programes de recerca orientats en l'àmbit de la recerca i la innovació en salut.” We thank CERCA Programme/Generalitat de Catalunya for institutional support. This work is partially supported by ICREA under the ICREA Academia program. IP-G receives a grant from the Spanish Ministry of Education, Culture and Sports (FPU 17/01925). L.C.-B. is the recipient of a predoctoral fellowship from the Generalitat de Catalunya's Department of Universities (FI-DGR 2017). NB-T is supported by a postdoctoral fellowship (Juan de la Cierva-Formación, FJC2018-036016-I) MRBL was supported by “Miguel Servet Type I” program (CP15/00028) from the ISCIII-Madrid (Spain), cofinanced by the Fondo Europeo de Desarrollo Regional-FEDER. Acknowledgements
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Purpose: Coffee is rich in compounds such as polyphenols, caffeine, diterpenes, melanoidins and trigonelline, which can stimulate brain activity. Therefore, the possible association of coffee consumption with cognition is of considerable research interest. In this paper, we assess the association of coffee consumption and total dietary caffeine intake with the risk of poor cognitive functioning in a population of elderly overweight/obese adults with metabolic syndrome (MetS). Methods: PREDIMED-plus study participants who completed the Mini-Mental State Examination test (MMSE) (n = 6427; mean age = 65 ± 5 years) or a battery of neuropsychological tests were included in this cross-sectional analysis. Coffee consumption and total dietary caffeine intake were assessed at baseline using a food frequency questionnaire. Logistic regression models were fitted to evaluate the association between total, caffeinated and decaffeinated coffee consumption or total dietary caffeine intake and cognitive impairment. Results: Total coffee consumers and caffeinated coffee consumers had better cognitive functioning than non-consumers when measured by the MMSE and after adjusting for potential confounders (OR 0.63; 95% CI 0.44–0.90 and OR 0.56; 95% CI 0.38–0.83, respectively). Results were similar when cognitive performance was measured using the Clock Drawing Test (CDT) and Trail Making Test B (TMT-B). These associations were not observed for decaffeinated coffee consumption. Participants in the highest tertile of total dietary caffeine intake had lower odds of poor cognitive functioning than those in the reference tertile when screened by the MMSE (OR 0.64; 95% CI 0.47–0.87) or other neurophysiological tests evaluating a variety of cognitive domains (i.e., CDT and TMT-A). Conclusions: Coffee consumption and total dietary caffeine intake were associated with better cognitive functioning as measured by various neuropsychological tests in a Mediterranean cohort of elderly individuals with MetS. Trial registration: ISRCTN89898870. Registration date: July 24, 2014.
AB - Purpose: Coffee is rich in compounds such as polyphenols, caffeine, diterpenes, melanoidins and trigonelline, which can stimulate brain activity. Therefore, the possible association of coffee consumption with cognition is of considerable research interest. In this paper, we assess the association of coffee consumption and total dietary caffeine intake with the risk of poor cognitive functioning in a population of elderly overweight/obese adults with metabolic syndrome (MetS). Methods: PREDIMED-plus study participants who completed the Mini-Mental State Examination test (MMSE) (n = 6427; mean age = 65 ± 5 years) or a battery of neuropsychological tests were included in this cross-sectional analysis. Coffee consumption and total dietary caffeine intake were assessed at baseline using a food frequency questionnaire. Logistic regression models were fitted to evaluate the association between total, caffeinated and decaffeinated coffee consumption or total dietary caffeine intake and cognitive impairment. Results: Total coffee consumers and caffeinated coffee consumers had better cognitive functioning than non-consumers when measured by the MMSE and after adjusting for potential confounders (OR 0.63; 95% CI 0.44–0.90 and OR 0.56; 95% CI 0.38–0.83, respectively). Results were similar when cognitive performance was measured using the Clock Drawing Test (CDT) and Trail Making Test B (TMT-B). These associations were not observed for decaffeinated coffee consumption. Participants in the highest tertile of total dietary caffeine intake had lower odds of poor cognitive functioning than those in the reference tertile when screened by the MMSE (OR 0.64; 95% CI 0.47–0.87) or other neurophysiological tests evaluating a variety of cognitive domains (i.e., CDT and TMT-A). Conclusions: Coffee consumption and total dietary caffeine intake were associated with better cognitive functioning as measured by various neuropsychological tests in a Mediterranean cohort of elderly individuals with MetS. Trial registration: ISRCTN89898870. Registration date: July 24, 2014.
KW - Caffeine
KW - Coffee
KW - Cognitive impairment
KW - Mini-Mental State Examination
KW - PREDIMED-plus
UR - http://www.scopus.com/inward/record.url?scp=85096323948&partnerID=8YFLogxK
U2 - 10.1007/s00394-020-02415-w
DO - 10.1007/s00394-020-02415-w
M3 - Article
C2 - 33125576
AN - SCOPUS:85096323948
SN - 1436-6207
VL - 60
SP - 2381
EP - 2396
JO - European Journal of Nutrition
JF - European Journal of Nutrition
IS - 5
ER -